A Phase I/Randomized Phase II Study of MLN0128 vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma
Sponsor: |
Alliance |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ5401 |
U.S. Govt. ID: |
NCT02601209 |
Contact: |
Gary Schwartz, MD: 212-305-2055 / gks2123@cumc.columbia.edu |
This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
This study is closed
Investigator
Gary Schwartz, MD
Have you been diagnosed with bone or soft tissue sarcoma? |
Yes |
No |
Have you had at least one prior chemotherapy? |
Yes |
No |